Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Addict Biol ; 18(3): 425-33, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-21507157

RESUMEN

Molecular mechanisms of adaptive transformations caused by alcohol exposure on opioid dynorphin and nociceptin systems have been investigated in the rat brain. Alcohol was intragastrically administered to rats to resemble human drinking with several hours of exposure: water or alcohol (20% in water) at a dose of 1.5 g/kg three times daily for 1 or 5 days. The development of tolerance and dependence were recorded daily. Brains were dissected 30 minutes (1- and 5-day groups) or 1, 3 or 7 days after the last administration for the three other 5-day groups (groups under withdrawal). Specific alterations in opioid genes expression were ascertained. In the amygdala, an up-regulation of prodynorphin and pronociceptin was observed in the 1-day group; moreover, pronociceptin and the kappa opioid receptor mRNAs in the 5-day group and both peptide precursors in the 1-day withdrawal group were also up-regulated. In the prefrontal cortex, an increase in prodynorhin expression in the 1-day group was detected. These data indicate a relevant role of the dynorphinergic system in the negative hedonic states associated with multiple alcohol exposure. The pattern of alterations observed for the nociceptin system appears to be consistent with its role of functional antagonism towards the actions of ethanol associated with other opioid peptides. Our findings could help to the understanding of how alcohol differentially affects the opioid systems in the brain and also suggest the dynorphin and nociceptin systems as possible targets for the treatment and/or prevention of alcohol dependence.


Asunto(s)
Encéfalo/efectos de los fármacos , Depresores del Sistema Nervioso Central/farmacología , Dinorfinas/genética , Etanol/farmacología , Péptidos Opioides/genética , Consumo de Bebidas Alcohólicas/genética , Consumo de Bebidas Alcohólicas/metabolismo , Intoxicación Alcohólica/genética , Intoxicación Alcohólica/metabolismo , Amígdala del Cerebelo/metabolismo , Animales , Depresores del Sistema Nervioso Central/sangre , Relación Dosis-Respuesta a Droga , Dinorfinas/metabolismo , Encefalinas/metabolismo , Etanol/sangre , Expresión Génica , Masculino , Péptidos Opioides/metabolismo , Precursores de Proteínas/metabolismo , Ratas , Ratas Sprague-Dawley , Reflejo de Enderezamiento/efectos de los fármacos , Síndrome de Abstinencia a Sustancias/etiología , Nociceptina
2.
Minerva Med ; 110(1): 62-78, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30667206

RESUMEN

Chronic pain treatment represents one of the most complex clinical challenges and even though opioids exhibit particular efficacy on nociceptive pain, their use must be controlled to avoid the risk of adverse reactions. A useful approach, aimed at maintaining analgesia and mitigating side effects, is represented by the use of a new class of analgesics endowed of µ-opioid (MOR) receptor agonism and noradrenaline reuptake inhibition (NRI) mechanisms. Tapentadol is the progenitor of this new class of drugs called MOP-NRI. A literature review has been conducted to gain information about the efficacy and the tolerability profile of tapentadol shifting from MOR agonism (acute pain) to NRI activity (chronic pain). The tolerability and therapeutic safety of tapentadol in neuropathic pain models, as well as in clinical settings, has been analyzed showing a good gastrointestinal tolerability profile, a moderate effect on hormone levels (in healthy volunteers and in patients) and on cognitive performance, a lack of significant alteration of the electrocardiogram recording and no changes of the QT/QTc interval, a minimal effect on serotonin reuptake in vivo with a low risk of serotonin syndrome, a longer time for the onset of analgesic tolerance and a less occurrence of abuse liability compared to formulations containing other comparator compounds. Tapentadol represents a great innovation in chronic pain therapy with a unique analgesic profile different form classical opioids, therefore, thanks to its synergistic MOR-NRI action, it may be a good option for the treatment of chronic, neuropathic and mixed pain.


Asunto(s)
Inhibidores de Captación Adrenérgica/uso terapéutico , Analgésicos Opioides/uso terapéutico , Dolor Crónico/tratamiento farmacológico , Manejo del Dolor/métodos , Tapentadol/uso terapéutico , Analgésicos Opioides/farmacología , Humanos , Tapentadol/farmacología
3.
Front Behav Neurosci ; 11: 81, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28553209

RESUMEN

After decades of uncertainties and drawbacks, the study on the role and significance of acetaldehyde in the effects of ethanol seemed to have found its main paths. Accordingly, the effects of acetaldehyde, after its systemic or central administration and as obtained following ethanol metabolism, looked as they were extensively characterized. However, almost 5 years after this research appeared at its highest momentum, the investigations on this topic have been revitalized on at least three main directions: (1) the role and the behavioral significance of acetaldehyde in different phases of ethanol self-administration and in voluntary ethanol consumption; (2) the distinction, in the central effects of ethanol, between those arising from its non-metabolized fraction and those attributable to ethanol-derived acetaldehyde; and (3) the role of the acetaldehyde-dopamine condensation product, salsolinol. The present review article aims at presenting and discussing prospectively the most recent data accumulated following these three research pathways on this never-ending story in order to offer the most up-to-date synoptic critical view on such still unresolved and exciting topic.

4.
J Mol Neurosci ; 49(2): 312-9, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-22684622

RESUMEN

Several studies demonstrated the role of the endogenous opioid system in the development of susceptibility to alcohol dependence. Recently, we reported that binge intragastric administration of ethanol induces selective alterations of pronociceptin and prodynorphin gene expression in the rat amygdala complex depending on the days of exposures and on the development of tolerance and dependence. The aim of the present study was to investigate the potential epigenetic mechanisms leading to these alcohol-induced changes in gene expression. Specific histone modifications and DNA methylation at opioid peptide precursor promoters were analyzed by chromatin immunoprecipitation and real-time methylation-specific PCR, respectively. We found a linkage between gene expression alterations and epigenetic modulation at pronociceptin and prodynorphin promoters following alcohol treatment. In animals treated for 1 day, we observed a reversed correlation, with a decrease of histone 3 lysine 27 trimethylation (repressive mark) and an increase of histone 3 lysine 9 acetylation (activating mark), associated with both gene expression up-regulation. In rats treated with alcohol for up to 5 days, we found an increase in histone 3 lysine 9 acetylation in the pronociceptin promoter providing further evidence of the already proposed possible role for histone deacetylases for addiction treatment. No significant alterations in DNA methylation and histone 3 lysine 4 trimethylation following different alcohol exposures were present, suggesting the selectivity of epigenetic effects induced by alcohol. These data demonstrate that ethanol induces selective epigenetic changes, thus better defining the role of opioid peptides in the ethanol-induced effects in the amygdala complex.


Asunto(s)
Amígdala del Cerebelo/metabolismo , Encefalinas/metabolismo , Epigénesis Genética/efectos de los fármacos , Etanol/farmacología , Precursores de Proteínas/metabolismo , Receptores Opioides/metabolismo , Acetilación , Amígdala del Cerebelo/efectos de los fármacos , Animales , Secuencia de Bases , Metilación de ADN , Encefalinas/genética , Etanol/toxicidad , Expresión Génica/efectos de los fármacos , Histonas/metabolismo , Masculino , Datos de Secuencia Molecular , Precursores de Proteínas/genética , Procesamiento Proteico-Postraduccional , Ratas , Ratas Sprague-Dawley , Receptores Opioides/genética
5.
Biol Psychiatry ; 74(7): 511-9, 2013 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-23702428

RESUMEN

BACKGROUND: Abuse of heroin and prescription opiate medications has grown to disturbing levels. Opioids mediate their effects through mu opioid receptors (MOR), but minimal information exists regarding MOR-related striatal signaling relevant to the human condition. The striatum is a structure central to reward and habitual behavior and neurobiological changes in this region are thought to underlie the pathophysiology of addiction disorders. METHODS: We examined molecular mechanisms related to MOR in postmortem human brain striatal specimens from a homogenous European Caucasian population of heroin abusers and control subjects and in an animal model of heroin self-administration. Expression of ets-like kinase 1 (ELK1) was examined in relation to polymorphism of the MOR gene OPRM1 and drug history. RESULTS: A characteristic feature of heroin abusers was decreased expression of MOR and extracellular regulated kinase signaling networks, concomitant with dysregulation of the downstream transcription factor ELK1. Striatal ELK1 in heroin abusers associated with the polymorphism rs2075572 in OPRM1 in a genotype dose-dependent manner and correlated with documented history of heroin use, an effect reproduced in an animal model that emphasizes a direct relationship between repeated heroin exposure and ELK1 dysregulation. A central role of ELK1 was evidenced by an unbiased whole transcriptome microarray that revealed ~20% of downregulated genes in human heroin abusers are ELK1 targets. Using chromatin immune precipitation, we confirmed decreased ELK1 promoter occupancy of the target gene Use1. CONCLUSIONS: ELK1 is a potential key transcriptional regulatory factor in striatal disturbances associated with heroin abuse and relevant to genetic mutation of OPRM1.


Asunto(s)
Cuerpo Estriado/metabolismo , Dependencia de Heroína/metabolismo , Núcleo Accumbens/metabolismo , Receptores Opioides mu/metabolismo , Proteína Elk-1 con Dominio ets/metabolismo , Animales , Femenino , Dependencia de Heroína/genética , Humanos , Masculino , Polimorfismo Genético , Ratas , Ratas Long-Evans , Receptores Opioides mu/genética , Transducción de Señal , Proteína Elk-1 con Dominio ets/genética
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA